Efficacy and safety of anti-CGRP monoclonal antibodies for chronic migraine prophylaxis in patients treated with botulinum toxin A: A prospective monocentric study
Since the high burden of chronic migraine (CM), it is challenging to identify the best prevention treatment. Based on the preclinical evidence about the different therapeutic targets of onabotulinumtoxinA (BT-A), acting on C-fibers, and anti-CGRP monoclonal antibodies (mAbs), acting on Aδ-fibers, th...
Uloženo v:
| Hlavní autoři: | , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publishing
2024-10-01
|
| Edice: | Cephalalgia Reports |
| On-line přístup: | https://doi.org/10.1177/25158163241267310 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|